Lower US sales of generic Revlimid dragged down second-quarter earnings, but double-digit growth in base markets and the upcoming relaunch of semaglutide offer near-term relief. Mumbai: Dr Reddy’s Laboratories posted its results for the September quarter on Friday, with profit down 36% year-on-year to ₹925 crore and consolidated revenue down 1.5% on-year to ₹8,671 crore.